Improving COVID-19 vaccine coverage in patients with autoimmune and inflammatory diseases.,The Journal of Rheumatology

当前位置： X-MOL 学术 › J. Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Improving COVID-19 vaccine coverage in patients with autoimmune and inflammatory diseases.
The Journal of Rheumatology ( IF 3.6 ) Pub Date : 2021-10-15 , DOI: 10.3899/jrheum.210534
Tiphaine Goulenok ₁ , Chrystelle Francois ₁ , Céline Mendes ₁ , Fatima Farhi ₁ , Jean-Francois Alexandra ₁ , Diane Rouzaud ₁ , Thomas Papo _{1,

2} , Karim Sacre _{2,

3}

Affiliation

In the current SARS Cov-2 pandemic context, vaccination using mRNA Covid-19 vaccine has started in France in December 2020. Based on the risk for severe COVID-19, patients suffering from autoimmune diseases (AID) and receiving -or about to receive- steroids or immunosuppressive drugs have been prioritized for vaccination (1).

中文翻译：

提高自身免疫性疾病和炎症性疾病患者的 COVID-19 疫苗覆盖率。

在当前的 SARS Cov-2 大流行背景下，使用 mRNA Covid-19 疫苗的疫苗接种已于 2020 年 12 月在法国开始。基于严重 COVID-19 的风险，患有自身免疫性疾病 (AID) 并正在接受或即将接受的患者- 类固醇或免疫抑制药物已优先接种疫苗 (1)。

更新日期：2021-10-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文